News coverage about Hologic (NASDAQ:HOLX) has been trending somewhat positive recently, AlphaOne Sentiment Analysis reports. The research firm, a unit of Accern, identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Hologic earned a news impact score of 0.19 on AlphaOne’s scale. AlphaOne also assigned media stories about the medical equipment provider an impact score of 43 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have impacted Alpha One’s analysis:
- Hologic (HOLX) Presents At The William Blair 2017 Growth Stock Conference – Slideshow (seekingalpha.com)
- Hologic, Inc. (NASDAQ:HOLX) Short Interest increased by 47.32% – Shares Trading Down (highlightpress.com)
- ETFs with exposure to Hologic, Inc. : June 16, 2017 (finance.yahoo.com)
- Hologic Receives Expanded FDA 510(k) Clearance to Market Cynosure’s SculpSure® for Non-Invasive Body Contouring (Lipolysis) of Back, Inner and Outer Thighs (finance.yahoo.com)
- BRIEF-Hologic receives expanded FDA clearance to market Cynosure’s Sculpsure (feeds.reuters.com)
Hologic (NASDAQ:HOLX) traded down 0.89% during mid-day trading on Friday, hitting $44.32. 2,826,586 shares of the stock traded hands. Hologic has a 12 month low of $32.81 and a 12 month high of $46.05. The stock has a market cap of $12.41 billion, a P/E ratio of 15.89 and a beta of 0.94. The stock has a 50-day moving average price of $44.25 and a 200-day moving average price of $41.75.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.46 by $0.04. The firm had revenue of $715.40 million during the quarter, compared to analysts’ expectations of $685.24 million. Hologic had a net margin of 27.31% and a return on equity of 25.26%. The firm’s quarterly revenue was up 3.2% on a year-over-year basis. During the same quarter last year, the company posted $0.47 EPS. On average, equities analysts forecast that Hologic will post $2.01 earnings per share for the current year.
Several analysts have issued reports on HOLX shares. Stifel Nicolaus raised their price objective on shares of Hologic from $45.00 to $48.00 and gave the stock a “buy” rating in a research note on Thursday, May 11th. Leerink Swann reissued an “outperform” rating and issued a $52.00 price objective on shares of Hologic in a research note on Thursday, March 30th. Piper Jaffray Companies reissued an “overweight” rating and issued a $51.00 price objective on shares of Hologic in a research note on Tuesday, March 14th. Zacks Investment Research downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research note on Tuesday, May 23rd. Finally, BTIG Research reissued a “buy” rating and issued a $47.00 price objective on shares of Hologic in a research note on Sunday, May 14th. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $47.54.
In related news, Director Sally Crawford sold 16,969 shares of the stock in a transaction that occurred on Monday, April 24th. The shares were sold at an average price of $44.00, for a total transaction of $746,636.00. Following the completion of the transaction, the director now owns 157,305 shares of the company’s stock, valued at approximately $6,921,420. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Peter J. Valenti III sold 10,005 shares of the stock in a transaction that occurred on Tuesday, May 30th. The stock was sold at an average price of $43.44, for a total transaction of $434,617.20. Following the transaction, the insider now directly owns 20,994 shares of the company’s stock, valued at approximately $911,979.36. The disclosure for this sale can be found here. Insiders have sold a total of 118,252 shares of company stock valued at $5,158,821 in the last ninety days. 0.79% of the stock is currently owned by corporate insiders.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-hologic-holx-share-price/1916814.html
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.